Pearse Keane: Reinventing the Eye Examination with Deep Learning
Speaker: Pearse Keane (Moorfields Eye Hospital, UCL)
Title: Reinventing the Eye Examination with Deep Learning
Abstract: Ophthalmology is among the most technology-driven of the all the medical specialties, with treatments utilizing high-spec medical lasers and advanced microsurgical techniques, and diagnostics involving ultra-high resolution imaging. Ophthalmology is also at the forefront of many trailblazing research areas in healthcare, such as stem cell therapy, gene therapy, and - most recently - artificial intelligence. In July 2016, Moorfields announced a formal collaboration with DeepMind. This collaboration involves the sharing of >1,000,000 anonymised retinal scans with DeepMind to allow for the automated diagnosis of diseases such as age-related macular degeneration (AMD) and diabetic retinopathy (DR). In my presentation, I will describe the motivation - and urgent need - to apply deep learning to ophthalmology, the processes required to establish a research collaboration between the NHS and a company like DeepMind, the initial results of our research, and finally, why I believe that ophthalmology could be first branch of medicine to be fundamentally reinvented through the application of artificial intelligence.
Bio: Pearse Keane is a consultant ophthalmologist at Moorfields Eye Hospital, London and an associate professor at UCL Institute of Ophthalmology. He is originally from Ireland and received his medical degree from University College Dublin (UCD), graduating in 2002.
In 2016, he initiated a formal collaboration between Moorfields Eye Hospital and Google DeepMind, with the aim of developing artificial intelligence (AI) algorithms for the earlier detection and treatment of retinal disease. In August 2018, the first results of this collaboration were published in the journal, Nature Medicine. In May 2020, he jointly led work, again published in Nature Medicine, to develop an early warning system for age-related macular degeneration (AMD), by far the commonest cause of blindness in many countries.
In October 2019, he was included on the Evening Standard Progress1000 list of most influential Londoners (https://www.standard.co.uk/news/the1000) and in June 2020, he was profiled in The Economist (https://www.economist.com/technology-quarterly/2020/06/11/the-potential-and-the-pitfalls-of-medical-ai).
In 2020, he was listed on the “The Power List” by The Ophthalmologist magazine, a ranking of the Top 100 most influential people in the world of ophthalmology (https://theophthalmologist.com/power-list/2020).